Abstract |
Several studies suggest that nitric oxide (NO) production is impaired in diabetes mellitus. Reduced levels of NO could contribute to cardiovascular mortality. Furthermore, NO synthesis is impaired in glutathione (GSH)-depleted human umbilical vein endothelial cells and GSH is reduced in patients with type 2 diabetes mellitus (T2DM). We tested the hypothesis that treatment with GSH may improve platelet constitutive NO sinthase (cNOS) activity in patients with T2DM. Fifteen patients with T2DM underwent a treatment with GSH 600 mg/day i.m. for 10 days. With respect to the basal values on the 10th day of treatment, the red blood cell GSH concentration and platelets cNOS increased (1.4+/-0.1 vs 1.9+/-0.1 micromol/10(10) RBC, p<0.001 and 0.7+/-0.1 vs 2.9+/-0.2 fmol x min(-1) x 10(-9) PLTs, p<0.001, respectively) and the plasma PAI-1 levels diminished (81.4+/-3.7 vs 68.7+/-4.0 ng/ml, p<0.002). A negative correlation between the cNOS and the PAI-1 was found on the basal values. After a wash-out of 30 days the values of red blood cell GSH concentration, platelet cNOS activity and PAI-1 Ag returned to the basal levels. These data suggest that the administration of GSH, in patients with T2DM, is able to improve platelet cNOS activity together with a reduction of PAI-1.
|
Authors | V Martina, G A Bruno, E Zumpano, C Origlia, L Quaranta, G P Pescarmona |
Journal | Journal of endocrinological investigation
(J Endocrinol Invest)
Vol. 24
Issue 1
Pg. 37-41
(Jan 2001)
ISSN: 0391-4097 [Print] Italy |
PMID | 11227730
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Plasminogen Activator Inhibitor 1
- Nitric Oxide
- NOS3 protein, human
- Nitric Oxide Synthase
- Nitric Oxide Synthase Type III
- Glutathione
|
Topics |
- Aged
- Blood Platelets
(enzymology)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Endothelium, Vascular
(metabolism)
- Erythrocytes
(metabolism)
- Female
- Glutathione
(administration & dosage, blood, therapeutic use)
- Humans
- Male
- Middle Aged
- Nitric Oxide
(biosynthesis)
- Nitric Oxide Synthase
(blood)
- Nitric Oxide Synthase Type III
- Plasminogen Activator Inhibitor 1
(blood)
- Umbilical Veins
|